Search Result

Results for "

rat cortex

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (18) Adenylate Cyclase (1) Adrenergic Receptor (11) Amino Acid Derivatives (1) Aminopeptidase (1) Amyloid-β (1) Angiotensin Receptor (1) Apoptosis (4) Calcium Channel (4) CaMK (1) Cholecystokinin Receptor (2) Cholinesterase (ChE) (8) Cytochrome P450 (1) Dopamine Receptor (2) Dopamine Transporter (2) Drug Derivative (1) Drug Intermediate (1) Endogenous Metabolite (2) Environmental Pollutants (1) Epigenetic Reader Domain (2) ERK (2) GABA Receptor (5) Glycine Receptor (GlyR) (1) GlyT (2) GSK-3 (1) HDAC (1) Histamine Receptor (3) Histone Methyltransferase (1) iGluR (8) Isotope-Labeled Compounds (3) JNK (1) mAChR (6) mGluR (2) MOFs (1) Monoamine Transporter (1) nAChR (7) Neurokinin Receptor (3) NO Synthase (4) Opioid Receptor (1) PARP (1) Phosphatase (2) Phosphodiesterase (PDE) (1) Reactive Oxygen Species (ROS) (1) Reference Standards (5) SARS-CoV (3) Sigma Receptor (1) Somatostatin Receptor (1) Tau Protein (1) Thyroid Hormone Receptor (1) Trk Receptor (1) α-synuclein (1)
By Research Areas:	Cancer (3) Cardiovascular Disease (10) Endocrinology (2) Inflammation/Immunology (9) Metabolic Disease (7) Neurological Disease (75)

By Targets:

5-HT Receptor (18)

Adenylate Cyclase (1)

Adrenergic Receptor (11)

Amino Acid Derivatives (1)

Aminopeptidase (1)

Amyloid-β (1)

Angiotensin Receptor (1)

Apoptosis (4)

Calcium Channel (4)

CaMK (1)

Cholecystokinin Receptor (2)

Cholinesterase (ChE) (8)

Cytochrome P450 (1)

Dopamine Receptor (2)

Dopamine Transporter (2)

Drug Derivative (1)

Drug Intermediate (1)

Endogenous Metabolite (2)

Environmental Pollutants (1)

Epigenetic Reader Domain (2)

ERK (2)

GABA Receptor (5)

Glycine Receptor (GlyR) (1)

GlyT (2)

GSK-3 (1)

HDAC (1)

Histamine Receptor (3)

Histone Methyltransferase (1)

iGluR (8)

Isotope-Labeled Compounds (3)

JNK (1)

mAChR (6)

mGluR (2)

MOFs (1)

Monoamine Transporter (1)

nAChR (7)

Neurokinin Receptor (3)

NO Synthase (4)

Opioid Receptor (1)

PARP (1)

Phosphatase (2)

Phosphodiesterase (PDE) (1)

Reactive Oxygen Species (ROS) (1)

Reference Standards (5)

SARS-CoV (3)

Sigma Receptor (1)

Somatostatin Receptor (1)

Tau Protein (1)

Thyroid Hormone Receptor (1)

Trk Receptor (1)

α-synuclein (1)

By Research Areas:

Cancer (3)

Cardiovascular Disease (10)

Endocrinology (2)

Inflammation/Immunology (9)

Metabolic Disease (7)

Neurological Disease (75)

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-18731

1400W Dihydrochloride Maximum Cited Publications 28 Publications Verification	NO Synthase Apoptosis	Cardiovascular Disease Inflammation/Immunology Cancer
1400W dihydrochloride is the dihydrochloride form of 1400W (HY-18730). 1400W is a slow, tight binding, and highly selective inducible nitric-oxide synthase (iNOS) inhibitor, with a K_d value ≤ 7 nM. 1400W inhibits iNOS induction in microglial cells, and reduces generation of NO, thereby mitigating oxidative stress and neuronal cell apoptosis in the rat cerebral cortex, and improving the spatial memory dysfunction caused by acute hypobaric hypoxia-reoxygenation .

HY-B1277

Trihexyphenidyl hydrochloride 3 Publications Verification	mAChR Cholinesterase (ChE)	Neurological Disease
Trihexyphenidyl hydrochloride is a selective and orally active M₁ muscarinic receptor antagonist with an IC₅₀ of 3.7 nM for rat cerebral cortex M1 muscarinic receptors. Trihexyphenidyl hydrochloride modulates cholinergic activity, countering acetylcholine supersensitivity in neural pathways. Trihexyphenidyl hydrochloride improves movement disorder, inhibits McN-A-343 (HY-107648)-induced pressor responses, vagally-induced bradycardia and vasodilatation. Trihexyphenidyl hydrochloride can be used for the research of Parkinson's disease. .

HY-100834

5,7-Dichlorokynurenic acid 1 Publications Verification 5,7-DCKA	iGluR	Neurological Disease
5,7-Dichlorokynurenic acid (5,7-DCKA) is a selective and competitive antagonist of the glycine site on NMDA receptor with a K_B of 65 nM. 5,7-Dichlorokynurenic acid reduces NMDA-induced neuron injury. 5,7-Dichlorokynurenic acid increases social interaction time, increases open arm exploration time, disinhibits suppressed conflict responding in rodent models. 5,7-Dichlorokynurenic acid exhibits anxiolytic-like activity in rodent models and supports exploration of glycine’s role in NMDA receptor-mediated synaptic transmission .

HY-101075

L-690330 1 Publications Verification	Phosphatase	Others
L-690330 is a competitive inhibitor of inositol monophosphatase (IMPase) with K_is of 0.27 and 0.19 μM for recombinant human and bovine IMPase, 0.30 and 0.42 μM for human and bovine frontal cortex IMPase, respectively. L-690330 exhibits 10-fold more sensitive than mouse and rat IMPase .

HY-18730

1400W Maximum Cited Publications 28 Publications Verification W1400	NO Synthase Apoptosis	Cardiovascular Disease Inflammation/Immunology Cancer
1400W is a slow, tight binding, and highly selective inducible nitric-oxide synthase (iNOS) inhibitor, with a K_d value ≤ 7 nM. 1400W inhibits iNOS induction in microglial cells, and reduces generation of NO, thereby mitigating oxidative stress and neuronal cell apoptosis in the rat cerebral cortex, and improving the spatial memory dysfunction caused by acute hypobaric hypoxia-reoxygenation .

HY-17550

Sunifiram DM-235	iGluR	Neurological Disease
Sunifiram (DM-235) is an ampakine-like compound and an agonist of AMPA receptor with oral activity. Sunifiram can increase the release of acetylcholine in the rat cerebral cortex and exhibits potent cognitive enhancement effects with better nootropic activity compared to piracetam (HY-B0585). Sunifiram is promising for research in neurodegenerative diseases such as mild cognitive impairment (MCI) and Alzheimer's disease (AD) .

HY-120380

FeTMPyP	MOFs PARP	Neurological Disease
FeTMPyP is an orally active poly (ADP-ribose) polymerase (PARP) inhibitor. FeTMPyP inhibits cell death, nitrotyrosine formation, and depolarization of mitochondrial transmembrane potential. FeTMPyP reduces homocysteine-induced nitrosative stress and partially restores TFEB protein and mRNA levels. FeTMPyP improves functional and behavioral deficits caused by chronic constriction injury in rats. FeTMPyP alleviates acute cerebral infarction in a rat model of middle cerebral artery occlusion with mild hyperglycemia. FeTMPyP can be used in studies related to neuropathic pain, renal aging, ischemic penumbra, and hyperglycemic stroke .

HY-P10638

TAT-CN21	CaMK	Cardiovascular Disease Neurological Disease
TAT-CN21 is a potent CaMKII inhibitor with an IC₅₀ of 77.2 nM. TAT-CN21 inhibits both calcium/calmodulin-dependent and autonomously activated CaMKII, blocks glutamate-induced translocation of CaMK IIα, and reverses the enhanced phosphorylation of CaMKII at Thr286 following excitotoxic injury. TAT-CN21 shows application potential in studies related to ischemic stroke by reducing neuronal excitotoxicity and exacerbating pre-existing long-term neuronal death prior to injury. TAT-CN21 improves definitive behaviors in rats with residual nerve injury without altering indicators such as mechanical/thermal hyperalgesia or spatial memory. TAT-CN21 can also be used in studies related to neuropathic pain .

HY-121186

Bevantolol hydrochloride	Adrenergic Receptor Calcium Channel	Cardiovascular Disease Neurological Disease Metabolic Disease
Bevantolol hydrochloride is a selective β1 and α1-adrenergic receptor antagonist with pK_i values of 7.83, 6.9 in rat cerebral cortex, respectively. Bevantolol hydrochloride is a potent Ca ²⁺ antagonist .

HY-W028142

Quipazine	5-HT Receptor SARS-CoV	Neurological Disease
Quipazine is a 5-HT agonist with a K_i value of 1.4 nM for displaces [3H]GR65630 from 5-HT3R in rat. Quipazine shows antiviral activity against SARS-CoV-2 with an EC₅₀ of 31.64 μM. Quipazine behaves as a 5-HT3R agonist in peripheral models. Quipazine can be used for neurological disease research .

HY-137683A

Guanosine 5'-O-2-thiodiphosphate trisodium GDPβS trisodium	Adenylate Cyclase	Cardiovascular Disease
Guanosine 5'-O-(2-thiodiphosphate) trisodium (GDPβS trisodium) is a non-hydrolyzable derivative of GDP. Guanosine 5'-O-(2-thiodiphosphate) trisodium acts as an inhibitor of adenylyl cyclase (AC) with a K_i value of 600 nM. In the absence of glutamic-pyruvic transaminase (GPT) in cerebral cortex membranes of rodent models, Guanosine 5'-O-(2-thiodiphosphate) trisodium partially activates AC with an EC₅₀ of 400 nM. Guanosine 5'-O-(2-thiodiphosphate) trisodium prevents norepinephrine-induced nitric oxide release in ventricular myocytes .

HY-103151

CP94253 hydrochloride	5-HT Receptor	Neurological Disease Metabolic Disease
CP94253 hydrochloride is an orally active, brain-penetrant and selective 5-HT_1B receptor agonist with an K_i of 2 nM. CP94253 hydrochloride induces antidepressant-like effects, waking enhancement, sleep inhibition, increased sleep latency, hyperlocomotion, and suppressed aggressive behavior. CP94253 hydrochloride can be used for the research of depression and heightened aggressive behavior .

HY-101333

CPPG (RS)-CPPG	mGluR	Neurological Disease
CPPG ((RS)-CPPG) is a potent group II/III mGlu receptors antagonist. CPPG exhibits some selectivity (approximately 20 fold) for group III (IC₅₀=2.2 nM) over group II (IC₅₀=46.2 nM) mGlu receptors in the rat cerebral cortex. CPPG has weak effects at group I mGlu receptors .

HY-W015876

L-Leucinol (+)-Leucinol	Aminopeptidase	Others
L-Leucinol ((+)-Leucinol) is a competitive aminopeptidase inhibitor with a K_i value of 17 μM. As a dietary intake inhibitor, L-Leucinol reduces the basal dietary leucine intake in rats via microinjection into the rat anterior piriform cortex .

HY-135115

Oleuropein Aglycone 3,4-DHPEA-EA	α-synuclein HDAC Adrenergic Receptor	Inflammation/Immunology
Oleuropein Aglycone (3,4-DHPEA-EA) is a polyphenol and the aglycone form of oleuropein (HY-N0292), formed by enzymatic, acidic or acetylated hydrolysis of oleuropein. Dietary intake of oleuropein Aglycone (50 mg/kg diet) increases the number of neuronal autophagic vesicles, reverses cognitive deficits in the TgCRND8 transgenic mouse model of Alzheimer's disease, and reduces the levels of histone deacetylase 2 (HDAC2) in the cortex and hippocampus. Oleuropein Aglycone increases urinary norepinephrine, interscapular brown adipose tissue epinephrine, and UCP1 protein levels, and reduced plasma leptin levels and total abdominal adipose tissue weight in a rat model of high-fat diet-induced obesity. Oleuropein Aglycone also reduced lung neutrophil infiltration, lipid peroxidation, and IL-1β levels in a mouse model of carrageenan-induced pleurisy.

HY-118301

ADX71441	GABA Receptor 5-HT Receptor	Neurological Disease
ADX71441 is an orally active, blood-brain barrier penetrant positive allosteric modulator of GABA_B receptor. ADX71441 potentiates the activity of endogenous GABA at GABA_B receptor, with an EC₅₀ of 96 nM. ADX71441 functionally inhibits adenosine transporters and 5-HT_2B receptor. ADX71441 produces anxiolytic-like, analgesic, muscle relaxant, hypothermic and overactive bladder inhibitory effects, reduces acute locomotor activity levels, decreases voluntary intake of alcohol and saccharin, attenuates stress-induced neuronal activation, and exhibits anti-hyperalgesic activity .

HY-W203728

L-β-Imidazolelactic acid	Amino Acid Derivatives	Neurological Disease
L-β-Imidazolelactic acid is a histidine derivative and an oxidizing agent that can trigger antioxidant effects in the brain cortex of rats .

HY-103509

NNC 05-2090 hydrochloride	GABA Receptor	Neurological Disease
NNC 05-2090 hydrochloride is a GABA uptake inhibitor and inhibitor of the β-GABA transporter (BGT-1) (IC_{50< /sub>}: 10.6 μM). NNC 05-2090 hydrochloride also inhibits mGAT2 with a K_i value of 1.4 μM. NNC 05-2090 has anticonvulsant activity and can be used in the study of epilepsy and neurological diseases .

HY-P1212

Cortistatin 14 (mouse, rat) CST-14 (mouse, rat)	Somatostatin Receptor	Neurological Disease
Cortistatin 14, mouse, rat (CST-14, human, rat), a neuropeptide with neuronal depressant and sleep modulating properties, can bind to all five cloned somatostatin receptors (SSTRs) and ghrelin receptor to exert its biological activities and co-exists with GABA within the cortex and hippocampus .

HY-12959A

Repinotan hydrochloride BAY x 3702	5-HT Receptor	Neurological Disease
Repinotan hydrochloride (BAY x 3702) is a potent, selective, brain-penetrant and orally active 5-HT1A receptor agonist, with K_i values of 0.19 nM (calf hippocampus), 0.25 nM (rat and human cortex), and 0.59 nM (rat hippocampus Repinotan hydrochloride has a weak affinity for other related receptors. Repinotan hydrochloride has pronounced neuroprotective effects .

HY-101046

Quipazine dimaleate	5-HT Receptor SARS-CoV	Neurological Disease
Quipazine dimaleate is a 5-HT agonist with a K_i value of 1.4 nM for displaces [3H]GR65630 from 5-HT3R in rat. Quipazine dimaleate shows antiviral activity against SARS-CoV-2 with an EC₅₀ of 31.64 μM. Quipazine dimaleate behaves as a 5-HT3R antagonist in peripheral models. Quipazine dimaleate can be used for neurological disease research .

HY-13225B

Rivanicline hemioxalate 1 Publications Verification RJR-2403 hemioxalate; (E)-Metanicotine hemioxalate	nAChR	Neurological Disease
Rivanicline (RJR-2403) hemioxalate is a neuronal nicotinic receptor agonist. Rivanicline hemioxalate is highly selective for the rat brain cortex nAChRs (K_i = 26 nM, EC₅₀ of 732 nM) and α4β2 subtype (K_i = 26 nM, EC₅₀ = 16 μM). Rivanicline hemioxalate can significantly restore the learning impairment and cognitive dysfunction. Rivanicline hemioxalate can be used for the study of neurodegenerative diseases (such as schizophrenia or Alzheimer's disease) .

HY-106584

Mosapramine Clospipramine	Drug Derivative Dopamine Receptor 5-HT Receptor	Neurological Disease
Mosapramine (Clospipramine) is an orally active antipsychotic agent and one of the metabolites of Clocapramine (HY-B2073) after oral absorption. Mosapramine exerts its effects by specifically binding to striatal dopamine D2 receptors and frontal lobe 5-HT2 receptors, with a D2/5-HT2 receptor occupancy ratio of 7.4. Mosapramine induces typical neuropharmacological responses in rat brain regions, including extrapyramidal symptoms, hyperprolactinemia, increased salivation, constipation, and upregulated Fos protein expression. Mosapramine also features a reduced incidence of weight loss. Mosapramine is applicable to research related to schizophrenia .

HY-10711A

ALX-5407 hydrochloride (R)-NFPS hydrochloride	GlyT	Neurological Disease
ALX-5407 ((R)-NFPS) hydrochloride is a selective and orally active glycine transporter GlyT1 inhibitor with an IC₅₀ value of 3 nM. ALX-5407 hydrochloride can be used the research of N-methyl-D-aspartate-receptor function and schizophrenia .

HY-W795507

Cyanopindolol	Adrenergic Receptor 5-HT Receptor	Neurological Disease
Cyanopindolol is an β3-adrenoceptor antagonist. Cyanopindolol is a potent and selective antagonist at the presynaptic serotonin autoreceptor in the rat brain cortex. Cyanopindolol has binding affinity for 5-HT1A and 5-HT1B receptor (K_i: 2.1 and 3 nM respectively) .

HY-P3801

[Glp5,(Me)Phe8,Sar9] Substance P (5-11) DiMe-C7	Neurokinin Receptor	Neurological Disease Metabolic Disease
[Glp5,(Me)Phe8,Sar9] Substance P (5-11) (DiMe-C7) is a Substance P (HY-P0201) analogue that has approximately the same effects as Substance P (HY-P0201) on neurokinin 1 receptor (NK1R) in rat brain, but with a much longer duration of action. [Glp5,(Me)Phe8,Sar9] Substance P (5-11) selectively activates dopamine metabolism in the mesencephalon and midbrain cortex of the rat brain. [Glp5,(Me)Phe8,Sar9] Substance P (5-11) also increases motor activity and induces recovery of addictive agent-seeking behavior in rats .

HY-120717

VU6001966	mGluR Cytochrome P450	Neurological Disease
VU6001966 is a brain-penetrant and selective mGlu2 receptor inhibitor. VU6001966 blocks mGlu2 receptor activity, counteracts LY379268 (HY-103558)-mediated blood-brain barrier protection and inflammatory cytokine dampening in microglia under inflammatory conditions. VU6001966 enhances antidepressant effects when combined with Scopolamine (HY-N0296). VU6001966 can be used for the research of major depressive disorder .

HY-103133

WAY208466 dihydrochloride	5-HT Receptor	Neurological Disease
WAY 208466 dihydrochloride is a potent and selective 5-HT₆ receptor agonist (EC₅₀=7.3 nM for the human 5-HT₆ receptor). WAY-208466 dihydrochloride elevates cortical GABA levels in rat frontal cortex . WAY 208466 dihydrochloride exhibits antidepressant and anxiolytic-like effects .

HY-B1277A

Trihexyphenidyl	mAChR Cholinesterase (ChE)	Cardiovascular Disease Neurological Disease
Trihexyphenidyl is a selective and orally active M₁ muscarinic receptor antagonist with an IC₅₀ of 3.7 nM for rat cerebral cortex M1 muscarinic receptors. Trihexyphenidyl modulates cholinergic activity, countering acetylcholine supersensitivity in neural pathways. Trihexyphenidyl improves movement disorder, inhibits McN-A-343 (HY-107648)-induced pressor responses, vagally-induced bradycardia and vasodilatation. Trihexyphenidyl can be used for the research of Parkinson's disease. .

HY-102043

PDM-631	Phosphodiesterase (PDE)	Neurological Disease
PDM-631 is a selective and orally active PDE2A inhibitor with blood-brain barrier penetration. PDM-631 exhibits potent inhibitory activity against human and rat recombinant PDE2A with IC₅₀ values of 1.5 nM and 4.2 nM, respectively. PDM-631 increases cGMP levels in the rat cerebral cortex. PDM-631 can be used for the study of schizophrenia and neurodegenerative disorders .

HY-170409

BNN27	Trk Receptor Apoptosis	Neurological Disease Inflammation/Immunology
BNN27 is the agonist for TrkA receptor and p75NTR receptor, that exhibits neurotrophic and anti-apoptotic effects. BNN27 increases the levels of glutamate, GABA, and glutamine in the rat hippocampus and prefrontal cortex, improves glutamate turnover. BNN27 exhibits neuroprotective efficacy in mouse amyotrophic lateral sclerosis (ALS) model, exhibits anti-inflammatory efficacy in experimental autoimmune encephalomyelitis (EAE) model, exhibits retinal protective efficacy in rat diabete models. BNN27 is blood-brain barrier penetrable .

HY-P3883

[DAla4] Substance P (4-11)	Neurokinin Receptor	Neurological Disease
[DAla4] Substance P (4-11) is an analog of Substance P (HY-P0201) that inhibits the binding of ¹²⁵I-Bolton Hunter-conjugated Eledoisin (HY-P0006) (IC₅₀ of 0.5 μM) and ¹²⁵I-Bolton Hunter-conjugated Substance P (IC₅₀ of 0.15 μM) to rat brain cortex membranes .

HY-13225A

Rivanicline RJR-2403; (E)-Metanicotine	nAChR	Neurological Disease
Rivanicline (RJR-2403) is a neuronal nicotinic receptor agonist. Rivanicline is highly selective for the rat brain cortex nAChRs (K_i = 26 nM, EC₅₀ of 732 nM) and α4β2 subtype (K_i = 26 nM, EC₅₀ = 16 μM). Rivanicline can significantly restore the learning impairment and cognitive dysfunction. Rivanicline can be used for the study of neurodegenerative diseases (such as schizophrenia or Alzheimer's disease) .

HY-W028142R

Quipazine (Standard)	Reference Standards 5-HT Receptor SARS-CoV	Neurological Disease
Quipazine is a 5-HT agonist with a Ki value of 1.4 nM for displaces [3H]GR65630 from 5-HT3R in rat. Quipazine shows antiviral activity against SARS-CoV-2 with an EC50 of 31.64 μM. Quipazine behaves as a 5-HT3R agonist in peripheral models. Quipazine can be used for neurological disease research .

HY-W794785

WAY 208466	5-HT Receptor	Neurological Disease
WAY 208466 is a selective 5-HT6 receptor agonist with an EC₅₀ of 7.3 nM. WAY-208466 increases GABA levels following both acute and chronic administration in the dorsolateral frontal cortex of rat models with stereotaxic surgery. WAY 208466 can be used for anxiety-related disorders like obsessive compulsive disorder (OCD) research .

HY-12959

Repinotan BAY x 3702 free base	5-HT Receptor	Neurological Disease
Repinotan (BAY x 3702 free base) is a potent, selective, brain-penetrant and orally active 5-HT1A receptor agonist, with K_i values of 0.19 nM (calf hippocampus), 0.25 nM (rat and human cortex), and 0.59 nM (rat hippocampus). Repinotan has a weak affinity for other related receptors. Repinotan has pronounced neuroprotective effects .

HY-10711

ALX-5407 (R)-NFPS	GlyT	Neurological Disease
ALX-5407 ((R)-NFPS) is a selective and orally active glycine transporter GlyT1 inhibitor with an IC₅₀ value of 3 nM. ALX-5407 can be used the research of N-methyl-D-aspartate-receptor function and schizophrenia .

HY-114753

Neboglamine CR-2249; XY-2401	iGluR	Neurological Disease
Neboglamine (CR-2249; XY-2401) is a modulator for N-methyl-D-aspartate (NMDA) receptor. Neboglamine increases the levels of fos-like immunoreactivity (FLI)-positive cells in the prefrontal cortex, nucleus accumbens, and lateral septal nucleus in rat models, .restores NMDA (HY-17551) -mediated neurotransmitter release, and inhibits phencyclidine-induced hyperlocomotion .

HY-105115

Abecarnil ZK 112119	GABA Receptor	Neurological Disease
Abecarnil (ZK 112119) is a ligand or a partial agonist for benzodiazepine (BZ) receptor. Abecarnil possesses anxiolytic and anticonvulsant properties. Abecarnil can act as a positive allosteric modulator of GABA_A receptor. Abecarnil inhibits the binding of the BZ [3H]lormetazepam to rat cerebral cortex membranes, with an IC₅₀ of 0.82 nM. Abecarnil can be used for epilepsy research .

HY-119495

JTP 2942	Thyroid Hormone Receptor	Neurological Disease
JTP 2942 is a thyrotropin-releasing hormone analogue. JTP 2942 can promote the release of Acetylcholine in the hippocampus and frontal cortex of rats. JTP 2942 possesses neuroprotective and cognitive-improving activities. JTP 2942 dose-dependently improves motor and neurological deficits in rat models of chronic focal cerebral ischemia. JTP 2942 can be used for the research of cerebral ischemia, motor neuron diseases, and other related conditions .

HY-13225

Rivanicline oxalate RJR-2403 oxalate; (E)-Metanicotine oxalate	nAChR	Neurological Disease
Rivanicline (RJR-2403) oxalate is a neuronal nicotinic receptor agonist. Rivanicline oxalate is highly selective for the rat brain cortex nAChRs (K_i = 26 nM, EC₅₀ of 732 nM) and α4β2 subtype (K_i = 26 nM, EC₅₀ = 16 μM). Rivanicline oxalate can significantly restore the learning impairment and cognitive dysfunction. Rivanicline oxalate can be used for the study of neurodegenerative diseases (such as schizophrenia or Alzheimer's disease) .

HY-120155

MS-377	Sigma Receptor iGluR	Neurological Disease
MS-377 is a selective and orally active sigma-1 receptor ligand (K_i=73 nM) with weak affinity for sigma-2 receptor (K_i=6900 nM) and no affinity for any other receptors including dopamine, serotonin, PCP site, glutamate, γ-aminobutylic acid, adenosine, adrenergic receptors, etc. (K_i: >10 μM). MS-377 indirectly modulates the NMDA receptor ion-channel complex. MS-377 is a antipsychotic agent. MS-377 inhibits PCP-induced behaviors by inhibition of the increase in dopamine and serotonin release in the rat medial prefrontal cortex. MS-377 can be used for research of schizophrenia .

HY-59201A

A-582941 dihydrochloride	ERK 5-HT Receptor Epigenetic Reader Domain nAChR	Neurological Disease Metabolic Disease
A-582941 dihydrochloride is a selective, orally active, blood-brain barrier-permeable α7 nAChR agonist, with K_i values of 10.8 nM and 17 nM in rat brain and human frontal cortex, respectively. A-582941 dihydrochloride exhibits agonistic activity at 5-HT3 receptors, with a K_i of 150 nM. A-582941 dihydrochloride triggers phosphorylation of ERK1/2 and CREB, inhibits GSK-3β via Ser-9 phosphorylation, increases acetylcholine release, induces the expression of Arc and c-Fos, activates brain regions associated with working memory and attention, and reduces cell death caused by nerve growth factor (NGF) deprivation. A-582941 dihydrochloride is applicable for the research of Alzheimer's disease and schizophrenia .

HY-W018475

Rizatriptan MK 462 free base	5-HT Receptor	Neurological Disease
Rizatriptan (MK 462 free base) is an orally active 5-HT_1B/5-HT_1D receptor agonist, with BBB permeability. Rizatriptan exerts significant anti-migraine effects by constricting intracranial and extracranial blood vessels and inhibiting neuropeptide release. Rizatriptan exhibits species- and tissue-specific metabolic characteristics; for example, it undergoes oxidative deamination mainly by MAO-A in the liver of brown rats, so co-administration with MAO-A inhibitors is prohibited. Rizatriptan may also exacerbate nitroglycerin-induced cutaneous allodynia, prolong the duration of central sensitization, and increase anxiety-like behavior and active drug-seeking behavior in mice. Rizatriptan has been widely used in studies related to migraine and medication-overuse headache .

HY-107563

ROS 234	Histamine Receptor	Inflammation/Immunology
ROS 234 is a potent H3 antagonist, with a pK_B of 9.46 for Guinea-pig ileum H₃-receptor, a pK_i of 8.90 for Rat cerebral cortex H₃-receptor, and a ED₅₀ of 19.12 mg/kg (ip) in ex vivo of Rat cerebral cortex. ROS 234 diaplays poor central access .

HY-107563A

ROS 234 dioxalate	Histamine Receptor	Inflammation/Immunology
ROS 234 dioxalate is a potent H3 antagonist, with a pK_B of 9.46 for Guinea-pig ileum H₃-receptor, a pK_i of 8.90 for Rat cerebral cortex H₃-receptor, and a ED₅₀ of 19.12 mg/kg (ip) in ex vivo of Rat cerebral cortex. ROS 234 dioxalate diaplays poor central access .

HY-106874B

rel-Delequamine rel-RS-15385-197	Adrenergic Receptor	Neurological Disease
rel-Delequamine (rel-RS-15385-197) is an orally active, brain-penetrant, potent and selective M₂-adrenoceptor antagonist and α₂-adrenoceptor antagonist. rel-Delequamine has a pK_i of 9.45 for α₂-adrenoceptors in the rat cortex. rel-Delequamine augments K ⁺-evoked release of noradrenaline with an EC₅₀ of 1 nM .

HY-P1588

Scyliorhinin II	Neurokinin Receptor	Neurological Disease Endocrinology
Scyliorhinin II is a selective neurokinin-3 receptor agonist, with a K_i of 2.5 nM for neurokinin-3 receptor in rat cerebral cortex.

HY-107562

JNJ 10181457 dihydrochloride	Histamine Receptor	Neurological Disease
JNJ-10181457 is a neutral, potent, brain-penetrant and selective non-imidazole H₃ antagonist which increases NE and ACh concentrations in rat frontal cortex. JNJ-10181457 can be used for neurological research .

HY-119409

Levophacetoperane Phacetoperane free base	Dopamine Transporter	Neurological Disease
Levophacetoperane (Phacetoperane free base) competitively inhibits the uptake of norepinephrin and dopamine .

Cat. No.	Product Name	Target	Research Area

HY-P10638

TAT-CN21	CaMK	Cardiovascular Disease Neurological Disease
TAT-CN21 is a potent CaMKII inhibitor with an IC₅₀ of 77.2 nM. TAT-CN21 inhibits both calcium/calmodulin-dependent and autonomously activated CaMKII, blocks glutamate-induced translocation of CaMK IIα, and reverses the enhanced phosphorylation of CaMKII at Thr286 following excitotoxic injury. TAT-CN21 shows application potential in studies related to ischemic stroke by reducing neuronal excitotoxicity and exacerbating pre-existing long-term neuronal death prior to injury. TAT-CN21 improves definitive behaviors in rats with residual nerve injury without altering indicators such as mechanical/thermal hyperalgesia or spatial memory. TAT-CN21 can also be used in studies related to neuropathic pain .

HY-P1212

Cortistatin 14 (mouse, rat) CST-14 (mouse, rat)	Somatostatin Receptor	Neurological Disease
Cortistatin 14, mouse, rat (CST-14, human, rat), a neuropeptide with neuronal depressant and sleep modulating properties, can bind to all five cloned somatostatin receptors (SSTRs) and ghrelin receptor to exert its biological activities and co-exists with GABA within the cortex and hippocampus .

HY-P3801

[Glp5,(Me)Phe8,Sar9] Substance P (5-11) DiMe-C7	Neurokinin Receptor	Neurological Disease Metabolic Disease
[Glp5,(Me)Phe8,Sar9] Substance P (5-11) (DiMe-C7) is a Substance P (HY-P0201) analogue that has approximately the same effects as Substance P (HY-P0201) on neurokinin 1 receptor (NK1R) in rat brain, but with a much longer duration of action. [Glp5,(Me)Phe8,Sar9] Substance P (5-11) selectively activates dopamine metabolism in the mesencephalon and midbrain cortex of the rat brain. [Glp5,(Me)Phe8,Sar9] Substance P (5-11) also increases motor activity and induces recovery of addictive agent-seeking behavior in rats .

HY-P3883

[DAla4] Substance P (4-11)	Neurokinin Receptor	Neurological Disease
[DAla4] Substance P (4-11) is an analog of Substance P (HY-P0201) that inhibits the binding of ¹²⁵I-Bolton Hunter-conjugated Eledoisin (HY-P0006) (IC₅₀ of 0.5 μM) and ¹²⁵I-Bolton Hunter-conjugated Substance P (IC₅₀ of 0.15 μM) to rat brain cortex membranes .

HY-P1588

Scyliorhinin II	Neurokinin Receptor	Neurological Disease Endocrinology
Scyliorhinin II is a selective neurokinin-3 receptor agonist, with a K_i of 2.5 nM for neurokinin-3 receptor in rat cerebral cortex.

Cat. No.	Product Name	Target	Research Area	Image

HY-P992426

NS101	Tau Protein	Neurological Disease
NS101 is an anti-FAM19A5 antibody with an IC₅₀ of 0.2 nM and a K_d of 111 pM, as well as blood-brain barrier permeability. NS101 binds to key amino acid residues of FAM19A5, thereby blocking the interaction of LRRC4B and disrupting the FAM19A5-LRRC4B complex. NS101 increases the dendritic spine density in hippocampal neurons and the prefrontal cortex, normalizes the dendritic spine elimination rate, elevates the frequencies of mEPSC and fEPSP, and promotes the transport of brain-derived FAM19A5 into the peripheral circulation. NS101 improves cognitive function in mouse models of Alzheimer's disease. NS101 can be used for research on Alzheimer's disease. The recommended isotype control is human IgG1 kappa (HY-P99001) .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N12616

2-Deoxy-D-ribose 1-phosphate	Structural Classification Natural Products Endogenous metabolite Source Classification	Drug Intermediate
2-Deoxy-D-ribose 1-phosphate is an intermediate in the metabolism of phosphoinositide, which is found in the rat cerebral cortex .

Cat. No.	Product Name	Chemical Structure

HY-B1277AS

Trihexyphenidyl-d5

Trihexyphenidyl-d₅ is deuterium labeled Trihexyphenidyl (HY-B1277A). Trihexyphenidyl is a selective and orally active M₁ muscarinic receptor antagonist with an IC₅₀ of 3.7 nM for rat cerebral cortex M1 muscarinic receptors. Trihexyphenidyl modulates cholinergic activity, countering acetylcholine supersensitivity in neural pathways. Trihexyphenidyl improves movement disorder, inhibits McN-A-343 (HY-107648)-induced pressor responses, vagally-induced bradycardia and vasodilatation. Trihexyphenidyl can be used for the research of Parkinson's disease. .

HY-B1277S

Trihexyphenidyl-d5 hydrochloride

Trihexyphenidyl-d₅ hydrochloride is deuterium labeled Trihexyphenidyl hydrochloride (HY-B1277). Trihexyphenidyl hydrochloride is a selective and orally active M₁ muscarinic receptor antagonist with an IC₅₀ of 3.7 nM for rat cerebral cortex M1 muscarinic receptors. Trihexyphenidyl hydrochloride modulates cholinergic activity, countering acetylcholine supersensitivity in neural pathways. Trihexyphenidyl hydrochloride improves movement disorder, inhibits McN-A-343 (HY-107648)-induced pressor responses, vagally-induced bradycardia and vasodilatation. Trihexyphenidyl hydrochloride can be used for the research of Parkinson's disease. .

HY-121186S

Bevantolol-d7 hydrochloride
Bevantolol-d₇ hydrochloride is the deuterium labeled Bevantolol hydrochloride (HY-121186). Bevantolol hydrochloride is a selective β1 and α1-adrenergic receptor antagonist with pK_i values of 7.83, 6.9 in rat cerebral cortex, respectively. Bevantolol hydrochloride is a potent Ca ²⁺ antagonist .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks